Holen Sie sich die Stockscreener-App
29.03
70.87%
12.04
Handel nachbörslich:
28.36
-0.67
-2.31%
Schlusskurs vom Vortag:
$16.99
Offen:
$29.52
24-Stunden-Volumen:
15.93M
Relative Volume:
34.72
Marktkapitalisierung:
$915.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+57.09%
1M Leistung:
+44.21%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$21.80
$33.20
1-Wochen-Bereich:
$15.97
$33.20
52-Wochen-Spanne:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Firmenname
Evommune Inc
Sektor
Branche
Telefon
(650) 223-7745
Adresse
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
29.03 | 535.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Eingeleitet | Oppenheimer | Outperform |
| 2026-01-08 | Eingeleitet | Raymond James | Strong Buy |
| 2026-01-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Eingeleitet | Evercore ISI | Outperform |
| 2025-12-01 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Evommune Inc Aktie (EVMN) Neueste Nachrichten
H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026 - Meyka
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis - MedCity News
Health Care Stocks Split As Evommune Pops On Eczema Data - Finimize
EVMN Stock Rating: Analyst Mitchell S. Kapoor Raises Price Targe - GuruFocus
Evommune stock price target raised to $55 by Evercore ISI on positive trial data By Investing.com - Investing.com India
Evommune stock price target raised to $55 by Evercore ISI on positive trial data - Investing.com
Evommune (NYSE:EVMN) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Evommune (NYSE:EVMN) Sets New 1-Year HighHere's What Happened - MarketBeat
Why Is Evommune Stock Soaring Today?Evommune (NYSE:EVMN) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune Stock Soars 51% Over Positive Top-Line Data From Atopic Dermatitis Study - Nasdaq
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate - PharmiWeb.com
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial - BioSpace
Evommune Says Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial; Shares Rise - marketscreener.com
Evommune wins in mid-stage trial for eczema drug (EVMN:NYSE) - Seeking Alpha
Evommune reports positive mid-stage data for eczema drug - statnews.com
EVMN: EVO301 achieved significant efficacy and safety in Phase 2a atopic dermatitis trial - TradingView
Evommune's Dupixent-like eczema data drive 75% stock rally - Fierce Biotech
Evommune Advances EVO301 After Positive Phase 2a Results - TipRanks
Evommune, Inc. Announces Positive Phase 2a Trial Results for EVO301 in Atopic Dermatitis - TradingView
Evommune soars on mid-stage atopic dermatitis data - FirstWord Pharma
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com UK
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com
Evommune reports EVO301 trial met primary endpoint - TipRanks
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Yahoo Finance
Evommune (NYSE:EVMN) Stock Price Down 5.3%Time to Sell? - MarketBeat
Evommune (NYSE:EVMN) Trading 10% HigherWhat's Next? - MarketBeat
Evommune (NYSE:EVMN) Shares Down 6.9%Here's Why - MarketBeat
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of Evommune (EVMN) with Outperform Recommendation - Nasdaq
Evommune (NYSE:EVMN) Now Covered by Oppenheimer - MarketBeat
Evommune (NYSE:EVMN) Stock Price Up 7.7%Still a Buy? - MarketBeat
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 - Finviz
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - FinancialContent
Evommune (NYSE:EVMN) Trading Down 7.7%Here's What Happened - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpWhat's Next? - MarketBeat
Evommune: Buy Rating Driven by Upcoming Phase II Readouts and Broad Inflammatory Disease Pipeline Potential - TipRanks
Raymond James Initiates Coverage on EVMN with Strong Buy Rating - GuruFocus
HC Wainwright Comments on Evommune FY2025 Earnings - MarketBeat
Raymond James initiates Evommune stock with Strong Buy rating, $40 target - Investing.com Nigeria
Evommune participates in a conference call with William Blair - MSN
Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch - TipRanks
Evommune stock initiated with Buy rating at H.C. Wainwright on urticaria potential - Investing.com Nigeria
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Evommune (EVMN) Receives 'Buy' Rating from HC Wainwright & Co. | - GuruFocus
Finanzdaten der Evommune Inc-Aktie (EVMN)
Es liegen keine Finanzdaten für Evommune Inc (EVMN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):